Objectives: Invasive pulmonary aspergillosis is associated with high mortality. To assess new antifungal therapy options, animal models have to be developed to assess, in an appropriate setting, the activity of new drugs.
Introduction
Invasive pulmonary aspergillosis is associated with a high mortality rate in humans. 1, 2 No reliable in vitro testing is available that could make predictions on the efficacy of various therapy options in humans and breakpoints are not yet identified especially for newer antifungal agents. Due to these limitations, animal models must be developed to assess the activity of these drugs in appropriate disease and host settings. Frequently antifungal agents are evaluated in disseminated fungal diseases of animal models.
Therefore, animal models are crucial for the preclinical evaluation of new antifungal agents. Further, the advantages of animal models are their potential for pharmacological and biological evaluation. Additionally, different disease models are accessible.
Posaconazole is an extended-spectrum triazole that demonstrates a broad in vitro antifungal spectrum. Posaconazole has shown in vitro, in vivo and clinical activity against various fungal pathogens, including Aspergillus spp., Candida spp., Cryptococcus neoformans, Coccidioides immitis, Histoplasma capsulatum, Blastomyces dermatitidis, zygomycetes and Fusarium.
Amphotericin B has broad activity against numerous fungi, however, its clinical use is frequently limited by an unfavourable safety profile, most notably dose-limiting nephrotoxicity in humans. 6, 7 An animal model with continuously immunocompromised rats was established to study antifungal agents ( posaconazole and amphotericin B) in invasive pulmonary aspergillosis.
Methods
The original model consisted of Sprague-Dawley rats which were treated with cortisone acetate, infected intratracheally with 10 6 conidia of Aspergillus fumigatus and followed daily for survival. 8 A modification of this model was used, since in our hands, not all rats became ill within the preset time of 7 days when the original dosage of cortisone acetate was administered.
Preparation of inocula
A. fumigatus, strain H11-20, was used for the experiments. H11-20 was isolated from a rat dying of spontaneously acquired pulmonary aspergillosis while on steroid treatment. 9 The isolate was incubated on Sabouraud dextrose agar plates at 358C for 4-5 days to form conidia. The conidia were harvested in 0.05% (v/v) Tween 80 in saline and filtered through several layers of sterile gauze. Conidia were counted with a haemocytometer. The final suspension was diluted in normal saline to a concentration of 10 7 conidia/mL. The conidial suspension was used within 24 h and stored until application at 48C.
Rats
Male albino CD rats (Charles River Laboratories, Sulzfeld, Germany; 125 -150 g) received doxycycline (200 mg dissolved in 750 mL of drinking water) ad libitum for the entire duration of the experiment. All animals were housed in groups of three rats per cage. Cages were inspected daily during the entire experiment. This animal experiment had an approval by the local authorities and was in accordance with laws for animal housing and care.
Immunosuppression
Rats were fed a protein-free diet and additionally given 12 mg/kg dexamethasone subcutaneously three times weekly during the whole experiment. After 2 weeks of this pretreatment, the rats were infected with A. fumigatus ( Figure 1 ).
Infection
Rats were anaesthetized by intraperitoneal injection of ketamine hydrochloride and xylazine. The trachea was revealed by surgery. The appropriate number of conidia in a volume of 0.1 mL of normal saline was slowly administered into the trachea by a 27 gauge needle with a syringe. Rats had fully recovered within 1 h of the procedure, and no deaths resulted from the inoculation procedure. Antifungal treatment was initiated within 1 h after infection and continued for 7 days. Ten rats were in each group; one untreated group served as a control. Rats appearing moribund or surviving 2 weeks after the end of treatment were sacrificed.
Antifungal treatment
Posaconazole (Noxafil w ; Schering-Plough, Kenilworth, NJ, USA) was made available by Schering-Plough. The suspension had a concentration of 40 mg/mL and is stable at room temperature. The suspension was diluted in sterile water to a concentration of 1 mg/mL and was stored at room temperature in the dark until use. Posaconazole was administered at doses of 2, 4, 10 and 20 mg/kg via gavage. Amphotericin B was purchased as the sodium deoxycholate formulation (Bristol-Myers Squibb, Germany) and was dissolved in 5% dextrose to produce a stock solution of 5 mg/mL. The drug stock was diluted in sterile water to produce the required concentration of 1 mg/mL. The stock solution was stored at 48C in the dark. Amphotericin B was administered at doses of 2 and 4 mg/kg intraperitoneally. All dilutions were newly prepared for each experimental therapy cycle (1 week).
Fungal cultures
The main organ of interest for this experiment was the lung. Organs used for fungal culture were removed using a sterile technique and mechanically homogenized in sterile saline. Homogenates were further diluted in normal saline and quantitatively cultured for 48 h on Sabouraud dextrose agar plates at 358C. Colonies visible on plates were counted to calculate the remaining fungal burden of the lung. Plates without any visible colonies were kept for an additional 5 days before they were discarded. Fungal burden was expressed as log 10 cfu/g of lung tissue.
Susceptibility testing
Portions of 0.1 mL of each spore suspension were added to microdilution tray wells that contained no drug (control wells) or amphotericin B. Plates were incubated at 358C for 48 h. The lowest concentration of test drug that prevented visible growth was considered the MIC. Strain H11-20 was tested at least twice against amphotericin B on at least 2 days. Distinct endpoints for amphotericin B were visible after 48 h of incubation. 10 An Etest w (AB Biodisk, Solana, Sweden) was used for testing susceptibility to posaconazole. This test was utilized due to its easier procedure and was performed twice. The Etest is considered consistent with the standard testing by CLSI.
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Statistical analysis
Survival was evaluated by log-rank analysis and compared pairwise by the Log-Rank test. Tissue fungal burden results were compared by non-parametric Mann-Whitney test. A P value of 0.05 was considered significant. All calculations were performed with GraphPad Prism Version 5.0. 
Results
MICs of amphotericin B and posaconazole for
Discussion
This study developed a rat animal model of non-disseminated invasive pulmonary aspergillosis in a non-neutropenic immunosuppressed state. The purpose of this model was to mimic invasive pulmonary aspergillosis, which is the most frequent manifestation of invasive aspergillosis in humans.
The majority of murine and rodent models for invasive aspergillosis use neutropenia and disseminated disease, which seldom occurs in humans as compared with invasive pulmonary disease. These animal models were usually developed to study the activity of antifungal drugs. 12, 13 So far there is no consensus on which model can be used ideally. Nevertheless, risk factors for invasive aspergillosis have been identified in various host groups including allogeneic stem cell recipients. Such risk factors for this specific risk group are prolonged neutropenia, graft failure, graft versus host disease and steroid exposure. 14, 15 This animal model was intended to mimic the immune state caused by steroid therapy in such patients. Dexamethasone was chosen since the corticosteroid potency is the highest. Important to that matter was the continuous immunosuppression with steroids since their withdrawal would allow the immune system to rapidly recover. 16 The intratracheal model used in this study provided a fixed spore count to each animal, in contrast to the application of conidia by intranasal aspiration which may be unreliable, or by use of inhalation chambers which have the disadvantage of possible differences in the quantity of conidia inhaled, due to variations in the respiratory rates of the animals. The invasiveness of the intratracheal procedure was well tolerated and no procedural deaths occurred.
Formal pharmacokinetic analyses were not performed in this study, but those results have been reported previously and were used for the treatment range in our model. 17 Both posaconazole and amphotericin B do not immediately achieve high and effective tissue levels allowing immediate application of the agents within the hour of conidia application. The results from this animal model confirmed previously published results with posaconazole but in a different immunocompromised setting and disease model. 18 -21 In our study, posaconazole at the highest dosage tested was able to nearly sterilize the lungs of most rats from A. fumigatus. The non-significant difference in survival rate might be attributable to the low numbers of animals in the group (underpowered study). The comparison of the fungal load in the lower dosage range might be misleading since no fixed time point was set for organ removal.
This model of experimental invasive pulmonary aspergillosis in immunocompromised outbred rats mimicked an immune situation similar to that of patients treated with corticosteroids. Infection without therapy resulted in death within 7 days. Pulmonary infection did not spread to other organs, although this was not studied thoroughly (data not shown). This model could be useful to study disease mechanism and various different therapeutic options. Posaconazole and amphotericin B in this model were effective in a dose-dependent manner.
